

# Short leukocyte telomere length predicts incidence and progression of carotid atherosclerosis in American Indians: The Strong Heart Family Study

Shufeng Chen<sup>1,2</sup>, Jue Lin<sup>3</sup>, Tet Matsuguchi<sup>3</sup>, Elizabeth Blackburn<sup>3</sup>, Fawn Yeh<sup>4</sup>, Lyle G. Best<sup>5</sup>, Richard B. Devereux<sup>6</sup>, Elisa T. Lee<sup>4</sup>, Barbara V. Howard<sup>7</sup>, Mary J. Roman<sup>6</sup>, and Jinying Zhao<sup>1</sup>

<sup>1</sup>Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA 70112, USA;

<sup>2</sup>Department of Evidence Based Medicine and Division of Population Genetics, State Key Laboratory of Cardiovascular Disease, Cardiovascular Institute and Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;

<sup>3</sup>Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94143, USA;

<sup>4</sup>Center for American Indian Health Research, University of Oklahoma Health Science Center, Oklahoma City, OK 73104, USA;

<sup>5</sup>Missouri Breaks Industries Research Inc, Timber Lake, SD 57656, USA;

<sup>6</sup>Weill Cornell Medical College, New York, NY 10065, USA;

<sup>7</sup>Medstar Research Institute and Georgetown and Howard Universities Centers for Translational Sciences, Washington, DC 20007, USA.

**Key words:** leukocyte telomere length, carotid atherosclerosis, risk prediction, American Indians, Strong Heart Study

**Received:** 4/14/14; **Accepted:** 5/23/14; **Published:** 5/28/14

**Correspondence to:** Jinying Zhao, MD/PhD **E-mail:** [jzhao5@tulane.edu](mailto:jzhao5@tulane.edu)

**Copyright:** © Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

**Abstract:** Short leukocyte telomere length (LTL) has been associated with atherosclerosis in cross-sectional studies, but the prospective relationship between telomere shortening and risk of developing carotid atherosclerosis has not been well-established. This study examines whether LTL at baseline predicts incidence and progression of carotid atherosclerosis in American Indians in the Strong Heart Study. The analysis included 2,819 participants who were free of overt cardiovascular disease at baseline (2001-2003) and were followed through the end of 2006-2009 (average 5.5-yr follow-up). Discrete atherosclerotic plaque was defined as focal protrusion with an arterial wall thickness  $\geq 50\%$  the surrounding wall. Carotid progression was defined as having a higher plaque score at the end of study follow-up compared to baseline. Associations of LTL with incidence and progression of carotid plaque were examined using Cox proportional hazard regression, adjusting for standard coronary risk factors. Compared to participants in the highest LTL tertile, those in the lowest tertile had significantly elevated risk for both incident plaque (HR, 1.49; 95% CI, 1.09–2.03) and plaque progression (HR, 1.61; 95% CI, 1.26–2.07). Our results provide initial evidence for a potential prognostic utility of LTL in risk prediction for atherosclerosis.

## INTRODUCTION

Telomeres are special chromatin structures and associated proteins at the end of each chromosome that protect chromosomes from degradation and recombination. They are formed by tandem repeats

made up of TTAGGG sequence in vertebrates[1]. Telomere length progressively shortens with each cell division to a critical length, called the Hayflick limit,[2] beyond which cell enters senescent state, resulting in a cascade of negative biological processes. Shorter leukocyte telomere length (LTL) has been associated

with a variety of age-related disorders, such as atherosclerotic cardiovascular diseases (CVD), [3] diabetes, [4] and cancer [5].

Atherosclerosis is an age-related disorder characterized by atherosclerotic plaque with variable arterial wall thickening. The atherosclerotic plaques comprise inflammatory cells, vascular smooth muscle cells, their secreted products, and intracellular and extracellular lipids. Increased number of senescent cells has been observed in vascular smooth muscle cells, endothelial cells and macrophages in aged arteries and atherosclerotic plaque [6-8]. Cross-sectional epidemiological studies have demonstrated an association of shorter telomere length with atherosclerosis and atherosclerotic CVD, [3, 9-12] but results were inconsistent across studies [13]. Among the very few longitudinal studies, shortened LTL was associated with all-cause mortality in patients with stable coronary artery disease [14] or type 1 diabetes [15], but no study has examined the potential role of telomere shortening in development and progression of carotid atherosclerosis in a large, community-based

cohort. The current study seeks to investigate whether LTL could be a potential prognostic factor predicting progression of carotid atherosclerosis in a prospectively examined population of American Indians participating in the Strong Heart Family Study (SHFS).

## RESULTS

### Characteristics of study participants at baseline and end of follow-up

LTL was significantly and inversely correlated with age ( $r = -0.33$ ,  $P < 0.0001$ ). Women had significantly longer LTL than men after adjusting for age ( $1.02 \pm 0.01$  vs.  $1.00 \pm 0.01$ , age-adjusted  $P = 0.03$ ). Of the 2,819 individuals with no overt CVD at baseline, 544 exhibited plaque progression after a mean follow-up period of 5.4 years, among whom 357 subjects (141 men, 216 women) developed new plaque and 187 (70 men, 117 women) had higher plaque score compared to baseline. Subjects with plaque progression had shorter LTL than those without ( $0.95 \pm 0.20$  vs.  $1.00 \pm 0.23$ ,  $P < 0.001$ ).

**Table 1.** Baseline characteristics of study participants with no prevalent CVD ( $n=2,819$ )

Variables	Mean $\pm$ SD or $n$ (%)
Leukocyte telomere length	0.99 $\pm$ 0.23
Age, years	38.5 $\pm$ 15.8
Men, $n$ (%)	1056 (37.5%)
Body mass index, kg/m <sup>2</sup>	32.4 $\pm$ 7.9
Systolic blood pressure, mmHg	121.6 $\pm$ 16.0
Diastolic blood pressure, mmHg	76.3 $\pm$ 11.0
Total cholesterol, mg/dl	180.6 $\pm$ 36.9
Triglyceride, mg/dl	164.1 $\pm$ 135.4
Low-density lipoprotein cholesterol, mg/dl	98.1 $\pm$ 29.0
High-density lipoprotein cholesterol, mg/dl	51.0 $\pm$ 14.4
Fasting glucose, mg/dl	113.1 $\pm$ 52.1
Estimated glomerular filtration rate, ml/min/1.73m <sup>2</sup>	102.1 $\pm$ 26.7
Current smoking, $n$ (%)	971 (34.5)
Current drinking, $n$ (%)	1661 (59.1)
Hypertension, $n$ (%)	841 (29.9)
Diabetes, $n$ (%)	586 (20.8)
Prevalent carotid plaque, $n$ (%)	728 (25.8)
Plaque progression, $n$ (%)	544 (19.3)
Incident carotid plaque, $n$ (%)	357 (17.1)

**Table 2.** Clinical correlates of LTL among participants with no prevalent CVD at baseline ( $n=2,819$ )

Variables	Correlation coefficient**	P value*
Body mass index	-0.13	<0.0001
Systolic blood pressure	0.04	0.4
Diastolic blood pressure	0.01	0.8
Total cholesterol	-0.03	0.2
Triglyceride	-0.04	0.06
Low-density lipoprotein cholesterol	-0.02	0.2
High-density lipoprotein cholesterol	0.03	0.06
Fasting glucose	-0.07	0.03
Estimated glomerular filtration rate	-0.03	0.6
Current smoking*	–	0.6
Current drinking*	–	0.3

\*\* Adjusted for age and sex; \* P-values by generalized estimating equation to account for family relatedness.

Table 1 shows clinical characteristics of study participants at baseline. Age- and sex-adjusted correlations of LTL with traditional coronary risk factors are presented in Table 2. After adjustments for age and sex, LTL was significantly correlated with BMI ( $r = -0.13$ ,  $P < 0.0001$ ) and fasting glucose ( $r = -0.07$ ,  $P = 0.03$ ), but not other listed covariates.

Table 3 lists baseline characteristics of study participants according to LTL tertiles. Compared to subjects in the highest tertile of LTL (longest telomere length), those in the lowest tertile were significantly older, had higher mean BMI, total cholesterol, triglyceride and low-density lipoprotein cholesterol. Prevalence of diabetes was significantly higher among subjects with shorter LTL than those with longer LTL (age-adjusted  $P$  trend 0.0004).

### Prospective association of LTL with incidence and progression of carotid plaque

LTL was significantly associated with incidence and progression of carotid atherosclerosis, independent of potential confounders. In multivariate survival analyses that treated LTL as a continuous variable, the hazards for incidence and progression of carotid plaque were 0.48 (95% CI, 0.27–0.85) and 0.50 (95% CI, 0.32–0.81), respectively. In statistical analyses using LTL tertiles, subjects with shorter LTL (lowest tertile) were significantly more likely to develop new plaque (HR, 1.49, 95% CI, 1.09–2.03) or plaque progression (HR, 1.61; 95% CI, 1.26–2.07) compared to those with longer LTL (highest tertile). Multivariate-adjusted HRs and 95% CIs for incident plaque and plaque progression are shown in Table 4. Kaplan-Meier survival curves for incident plaque are plotted in Figure S1.

**Table 3.** Characteristics of study participants according to LTL tertiles (n=2,819)

Variables	Tertile 1 (N=939)	Tertile 2 (N=940)	Tertile 3 (N=940)	P value*
Age, years	44.5±15.3	39.1±15.2	32.0±14.3	<0.0001
Men, n (%)	345 (36.7)	366 (38.9)	345 (36.7)	0.9
LTL (T/S ratio)				
Mean	0.75±0.12	0.98±0.05	1.23±0.15	<0.0001**
Median	0.78	0.98	1.19	
Range	0.28-0.90	0.90-1.07	1.07-2.22	
Interquartile range	0.18	0.08	0.16	
Follow-up, years	5.1±1.0	5.5±1.1	5.6±1.1	0.1**
Prevalent plaque, n (%)	345 (36.7)	236 (25.1)	147 (15.6)	0.2**
Plaque progression, n (%)	221 (23.5)	198 (21.1)	125 (13.3)	0.07**
Incident plaque, n (%)	122 (20.5)	141 (20.0)	94 (11.9)	0.9**
Body mass index, kg/m <sup>2</sup>	33.6±8.1	32.5±7.9	31.1±7.5	0.0002**
SBP, mmHg	123.4±16.7	122.3±16.3	119.1±14.6	0.8**
DBP, mmHg	76.8±10.4	76.8±11.6	75.4±10.9	0.2**
Total cholesterol, mg/dl	184.1±36.8	183.1±36.6	174.6±36.6	0.02**
Triglyceride, mg/dl	173.8±141.7	169.5±129.0	149.0±134.2	0.05**
LDL-C, mg/dl	99.5±29.6	100.2±29.3	94.5±27.7	0.02**
HDL-C, mg/dl	51.2±14.1	50.5±14.8	51.1±14.4	0.1**
Fasting glucose, mg/dl	121.7±58.6	113.4±51.6	104.2±43.7	0.06**
eGFR, ml/min/1.73m <sup>2</sup>	97.9±28.0	101.7±26.5	106.7±25.0	0.5**
Current smoking, n (%)	305 (32.6)	329 (35.0)	337 (35.9)	0.8**
Current drinking, n (%)	527 (56.4)	539 (57.5)	595 (63.3)	0.1**
Hypertension, n (%)	347 (37.0)	298 (31.8)	196 (20.9)	0.4**
Diabetes, n (%)	281 (30.0)	194 (20.6)	111 (11.8)	<0.0001**

\* Correction for family relatedness by generalized estimating equation; \*\* Additionally adjusted for age at baseline. Abbreviations: LTL, leukocyte telomere length; T/S ratio, telomeric product (T)/single copy gene (S) product; eGFR, estimated glomerular filtration rate.

### Results of sensitivity analyses

Sensitivity analyses for incidence and progression of carotid plaque using PROC LIFEREG are shown in Table S1. Results show that additionally taking into account interval-censoring of the data did not change our results. After excluding participants with prevalent

diabetes, the associations of LTL with incident plaque (HR, 1.62; 95% CI, 1.14–2.31) and plaque progression (HR, 1.69; 95% CI, 1.27–2.25) remained statistically significant (Table S2). Further exclusion of participants with hypertension did not change our results (Table S3). In addition, results in LTL quartiles were similar to those in tertiles.

**Table 4.** Prospective association of LTL with incidence and progression of carotid plaque in American Indians participating in the Strong Heart Family Study

LTL	HR (95% CI)	P value
<b>Incident plaque (N=2,091)</b>		
<b>Model 1</b>		
Continuous LTL	0.43 (0.24-0.75)	0.003
Tertile 1 vs. Tertile 3	1.58 (1.16- 2.15)	0.004
Tertile 2 vs. Tertile 3	1.19 ( 0.88 - 1.60)	0.25
<b>Model 2</b>		
Continuous LTL	0.42 (0.24- 0.75)	0.003
Tertile 1 vs. Tertile 3	1.57 (1.15- 2.14)	0.004
Tertile 2 vs. Tertile 3	1.18 (0.88 - 1.59)	0.28
<b>Model 3</b>		
Continuous LTL	0.48 (0.27- 0.85)	0.01
Tertile 1 vs. Tertile 3	1.49 (1.09- 2.03)	0.01
Tertile 2 vs. Tertile 3	1.14 ( 0.85 - 1.54)	0.39
<b>Plaque progression (N=2,819)</b>		
<b>Model 1</b>		
Continuous LTL	0.45 (0.28 - 0.71)	0.0006
Tertile 1 vs. Tertile 3	1.72 (1.34 - 2.21)	<0.0001
Tertile 2 vs. Tertile 3	1.34 (1.06 - 1.69)	0.01
<b>Model 2</b>		
Continuous LTL	0.47 (0.30- 0.75)	0.001
Tertile 1 vs. Tertile 3	1.67 (1.31- 2.14)	<0.0001
Tertile 2 vs. Tertile 3	1.30 (1.03 - 1.64)	0.03
<b>Model 3</b>		
Continuous LTL	0.50 (0.32- 0.81)	0.004
Tertile 1 vs. Tertile 3	1.61 (1.26- 2.07)	0.0002
Tertile 2 vs. Tertile 3	1.22 (0.96 - 1.54)	0.10

Model 1: adjusted for age at baseline, sex and study center

Model 2: additionally adjusted for BMI, current smoking and alcohol drinking status

Model 3: further adjusted for diabetes, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and estimated glomerular filtration rate

## DISCUSSION

In a large, well-characterized prospective cohort of American Indians, we found that LTL significantly predicts incidence and progression of carotid atherosclerosis, independent of established cardiovascular risk factors including diabetes and hypertension. Subjects

with shorter LTL have significantly elevated risk of developing carotid atherosclerosis than those with longer telomeres, indicating that LTL could be a valuable prognostic marker for carotid atherosclerosis. Our study provides initial evidence for a prospective association of LTL with carotid atherosclerosis.

Previous studies have examined the association of LTL with subclinical atherosclerosis, [13, 16-18] most of which focused on cross-sectional analyses of ultrasonic measures in subgroups of patients or research subjects. For example, among men participating in the Framingham Heart Study, age-adjusted LTL was significantly associated with internal carotid artery intima-media thickness (IMT) in obese (BMI > 30 kg/m<sup>2</sup>), but not in non-obese men.[18] Another study reported negative association of LTL with common carotid IMT in subjects over 40 years old.[11] Shorter LTL was also associated with carotid artery plaque in hypertensive men[19] or elderly subjects (mean age 73 years old) [17]. In addition, LTL was negatively associated with coronary artery calcification in a low risk cohort free of prevalent CVD [20] and in an urban Arab population [21]. However, other studies did not find an association of LTL with subclinical atherosclerosis as measured by IMT [13]. Moreover, to our knowledge, the prospective association of LTL with incidence or progression of carotid plaque has not been previously examined.

In contrast to results regarding plaque progression, shorter LTL did not predict atherosclerotic progression assessed by an increase in IMT (data not shown) in our study population. Although IMT and plaque are highly correlated,[22] they may reflect different aspects of atherogenesis with distinctive relations to clinical outcomes.[23, 24] In general, IMT is considered as a measure of diffuse or early atherosclerosis as well as arteriosclerosis, whereas plaque is a direct manifestation of atherosclerosis that represents later stage of atherosclerosis more closely related to clinical events. The pathological processes leading to thickening of intima media and to plaque formation may also be different. [25, 26]. In the SHFS, we measured carotid IMT in regions free of plaque, which is different from many previous studies that measured carotid artery wall thickness regardless of the absence or presence of plaque. [27, 28]. In previous studies, we have reported different heritability of subclinical atherosclerosis in the SHFS, [29] suggesting potential differences in genetic and/or environmental mechanisms influencing inter-individual variability in IMT and plaque. We also found that carotid plaque, but not IMT, significantly predicts CVD events in participants of the SHS, [24] further highlighting the potential differences in biological mechanisms leading to intima-media thickening and plaque formation between vascular beds. In a recent study, shorter LTL predicts advanced, but not early, atherogenesis, consistent with our findings of association between telomere shortening and discrete

plaque but not diffuse IMT.[30] Therefore, the differential effect of LTL on atherosclerosis as measured by carotid plaque, but not IMT, observed in our study is in agreement with previous findings and suggests that carotid IMT and plaque merit separate analysis in future research.

Our study has several limitations. First, we measured LTL using a PCR-based assay that does not quantify absolute telomere length; hence we were unable to examine the differences in absolute telomere length. However, the qPCR method requires much less amount of DNA than Southern blot and thus is well suited for large-scale epidemiological studies. Moreover, telomere lengths measured by these two methods are highly correlated [31]. Second, telomere lengths may vary among cells in the same tissue and among chromosomes in the same cell [32]. In this study, we only measured telomere length in blood leukocytes but not carotid plaque; however, obtaining plaque tissue is clinically impractical for large-scale epidemiological studies. In addition, previous studies have demonstrated that telomere length in different tissues may be highly correlated [33]. Moreover, the current study does not explain the mechanisms underlying the link between shortened telomere length and development of carotid atherosclerosis. Third, our findings were derived from a cohort of American Indians who suffer from a *high rate* of diabetes. However, all our statistical analyses adjusted for diabetes status, and excluding participants with diabetes did not change our results. In addition, diabetes prevalence is rising in many other populations, suggesting that our findings may be replicated in other settings. Fourth, although we were able to control many of the potential confounding variables, residual confounding by other factors including time-dependent factors cannot be entirely excluded. Finally, the prospective association of LTL with risk of carotid atherosclerosis identified in our study may not necessarily be causal because baseline factors influencing atherosclerosis, either unmeasured or imperfectly measured, may influence this apparently “causal” relationship.

In summary, shorter LTL significantly predicts increased risk of atherosclerosis development among participants in the SHFS, independent of known coronary risk factors. Our finding provides novel insights into the understanding of biological aging and its role in atherogenesis, which will potentially lead to novel therapeutic options of anti-aging to prevent atherosclerosis. Confirmation in individuals of other ethnic origins with different risk profiles or environment is warranted in future research.

## METHODS

Study population. The Strong Heart Study (SHS) is a longitudinal study of CVD and its risk factors among 13 American Indian communities residing in three geographic regions in Arizona, Oklahoma, and North and South Dakota. The Strong Heart Family Study (SHFS), a component of the SHS, was initiated in 2001-2003 by recruiting 3,665 tribal members (aged 14-93 years old) from 94 multigenerational families. Detailed study design and methods of the SHS have been described elsewhere.[34, 35] The SHS protocols were approved by the Institutional Review Boards of the Indian Health Service, the participating institutions, and the participating tribes. Written informed consent was obtained from each study participant.

All SHFS participants underwent carotid ultrasound examinations at baseline (2001-2003) and again after 5 years follow-up (2006-2009, 93% of surviving participants). The current analyses of plaque progression included 2,819 participants (1,056 men, 1,763 women) free of overt CVD at baseline. For incident carotid plaque, we further excluded participants with prevalent carotid plaque (n=728), leaving a final sample size of 2,091 (788 men, 1,303 women) for the incidence analyses.

Carotid ultrasonography. All SHFS study participants underwent carotid ultrasonography using Acuson Sequoia machines equipped with 7 MHz vascular probes on the day of the clinic visit using a standardized protocol as described previously.[24, 26] In brief, with the subject in the supine position, carotid arteries were extensively scanned for atherosclerotic plaque. The presence of discrete atherosclerotic plaque was defined as the presence of focal thickening at least 50% the surrounding wall, which was defined as the uninvolved intimal-medial thickness (IMT) adjacent to the plaque. This is a standard definition used in numerous epidemiologic studies, including the Atherosclerosis Risk in Communities Study (ARIC) [36]. Plaque score, a semi-quantitative measure of the extent of atherosclerosis, was calculated by the number of left and right segments (common carotid, bulb, internal carotid, external carotid) containing plaque; thus plaque score ranged from 0 to 8. [24] Incident plaque was identified if plaque was absent at baseline but plaque was detected at the end of study follow-up. Progression of carotid plaque was defined as a higher plaque score at follow-up compared to baseline. All ultrasound measurements were performed by trained research sonographers and interpreted by a single highly experienced cardiologist (Mary J. Roman) who was blinded to the clinical characteristics of study participants.

Measurement of leukocyte telomere length (LTL). LTL was measured by quantitative polymerase chain reaction (qPCR) in Dr. Blackburn's laboratory at UCSF. Detailed laboratory protocol and quality control procedures have been described previously [37-40]. Briefly, LTL was quantified by qPCR using a serially diluted standard DNA and the standard curve method. The ratio of the telomeric product vs. the single copy gene reflects the average length of the telomeres. A single copy gene was amplified in parallel to normalize the quantity of the input DNA. Each DNA sample was assayed three times and the mean value was used in statistical analysis. *For quality control, we included seven control DNA samples from various cancer cell lines in each assay plate.* These control samples allowed us to create standard curves, which were then integrated into a composite standard curve used for T and S concentration calculations. In addition, *4.1% of the total sample was assayed in duplicate. LTL of replicate samples were highly correlated ( $r = 0.95$ ,  $p < 0.0001$ ).* The intra- and inter-assay %CV was 4.6% and 6.9%, respectively. Lab technicians were blinded to any knowledge of clinical data.

Assessments of risk factors. The SHS consisted of a personal interview, a physical examination, and laboratory tests. The personal interview collected information for demographics, medical history, and lifestyle factors including smoking, alcohol intake, habitual diet and physical activity. The physical examination included anthropometric measures, blood pressure measurements and an examination of the heart and lungs. Fasting blood samples were collected to measure lipids, glucose, insulin, and inflammatory biomarkers. Urinary albumin and creatinine was measured in a spot urine sample collected on the day of clinical visit. Details of the study protocol and lab methods have been described previously.[34]

Current smoking was defined as smoking 100 or more cigarettes and currently smoking every day or some days. Alcohol consumption was determined by self-reported history of alcohol intake, the type of alcoholic beverages consumed, frequency of alcohol consumption, and average quantity consumed per day per week. Current drinking was defined as having had at least one alcoholic beverage in the 12 months prior interviews. Systolic and diastolic blood pressure were measured on the right arm with an appropriately sized cuff using a Baum mercury sphygmomanometer (WA Baum Co) after the participant had been resting in a seated position for 5 minutes. Anthropometric measures were obtained from each participant wearing light clothing and no shoes. Body mass index (BMI) was calculated as body weight in kilograms divided by the square of height in meters ( $\text{kg}/\text{m}^2$ ). Waist-to-hip ratio



was calculated as waist circumference divided by hip circumference. Hypertension was defined as blood pressure  $\geq 140/90$  mm Hg or current use of antihypertensive medications.[41] According to the American Diabetes Association criteria, diabetes was defined as fasting plasma glucose  $\geq 7.0$  mmol/L (126 mg/dl) or currently receiving insulin or oral hyperglycemic treatment [42].

Statistical analyses. The association of LTL (continuous variable) with traditional coronary risk factors was assessed by calculating partial correlation coefficients, adjusting for age at baseline. All statistical analyses were done using SAS 9.3 (SAS Institute, Inc., Cary, North Carolina).

Prospective association of LTL with incidence and progression of carotid plaque. The distribution of plaque-free time according to LTL tertiles was estimated by the Kaplan-Meier method.[43] Cox's proportional hazard model was used to assess the association of LTL with development of carotid plaque, adjusting for covariates at baseline [44].

We investigated whether LTL at baseline predicts future onset of carotid plaque and its progression using multivariate survival analysis, in which time (in years) to incident plaque (yes/no) or carotid plaque progression (yes/no) was the dependent variable and LTL (either continuous or in tertiles) was the independent variable, adjusting for baseline covariates described below. In this study, we are interested in both the occurrence of atherosclerotic plaque at the end of study follow-up and plaque-free time in atherosclerosis development. For this purpose, we used Cox proportional hazards models to capture both the "time" and the "event" components related to plaque development. Family relatedness was controlled by the shared frailty model implemented in PROC PHREG. We used the clinical examination date that plaque incidence or progression was identified as the date of diagnosis; otherwise follow-up was censored for participants who remained stable or free of carotid plaque at the end of follow-up.

Sensitivity analyses. Although we know that plaque onset or its progression took place between the two clinical visits, the exact time of their occurrences was not directly observed in present study. To examine whether and how such interval-censored data influence our results, we performed sensitivity analyses using PROC LIFEREG, which fits a Weibull distribution to interval-censored lifetime data by maximum likelihood estimation of distribution parameters [45]. In this procedure, coefficients describe the log of hazard function using time minus a constant for subjects with "event", thus it is different from coefficients obtained

from the PHREG procedure in proportional hazard model [45].

To examine the impact of potential confounders on our results, we constructed a series of hierarchical models: Model 1 adjusted for age at baseline, sex, and study center; Model 2 additionally adjusted for lifestyle factors including BMI, current smoking and alcohol drinking; Model 3 further adjusted for diabetes status, systolic blood pressure, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol, and estimated glomerular filtration rate (eGFR). Multivariate-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for each model.

Diabetes and hypertension are independent risk factors for atherosclerotic CVD.[46] To examine their potential impact on the association of LTL with development of carotid atherosclerosis, we conducted sensitivity analyses by first excluding participants with prevalent diabetes (n=586), and then further excluding subjects with hypertension (n=484) at baseline. *To examine the robustness* of our findings, we also categorized telomere data into quartiles.

## ACKNOWLEDGEMENTS

The authors would like to thank the SHFS participants, Indian Health Service facilities, and participating tribal communities for their extraordinary cooperation and involvement, which has contributed to the success of the SHFS. The views expressed in this article are those of the authors and do not necessarily reflect those of the Indian Health Service.

## Sources of Funding

This study was supported by National Institutes of Health grants R01DK091369, K01AG034259, R21HL092363 and cooperative agreement grants U01HL65520, U01HL41642, U01HL41652, U01HL41654, and U01HL65521. Dr. Chen is supported by a research training grant (D43TW009107) from NIH John E Fogarty International Center, Bethesda, MD.

## Conflict of interest statement

The authors of this manuscript declare no conflict of interests.

## REFERENCES

1. Cenci G, Ciapponi L and Gatti M. The mechanism of telomere protection: a comparison between *Drosophila* and humans. *Chromosoma*. 2005; 114:135-145.



2. Shay JW and Wright WE. Hayflick, his limit, and cellular ageing. *Nat Rev Mol Cell Biol.* 2000; 1:72-76.
3. Brouillette S, Singh RK, Thompson JR, Goodall AH and Samani NJ. White cell telomere length and risk of premature myocardial infarction. *Arterioscler Thromb Vasc Biol.* 2003; 23:842-846.
4. Shen Q, Zhao X, Yu L, Zhang Z, Zhou D, Kan M, Zhang D, Cao L, Xing Q, Yang Y, Xu H, He L and Liu Y. Association of leukocyte telomere length with type 2 diabetes in mainland Chinese populations. *J Clin Endocrinol Metab.* 2012; 97:1371-1374.
5. Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, Brandstatter A, Kronenberg F and Kiechl S. Telomere length and risk of incident cancer and cancer mortality. *JAMA.* 2010; 304:69-75.
6. Fyhrquist F, Saijonmaa O and Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease. *Nat Rev Cardiol.* 2013; 10:274-283.
7. Matthews C, Gorenne I, Scott S, Figg N, Kirkpatrick P, Ritchie A, Goddard M and Bennett M. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. *Circ Res.* 2006; 99:156-164.
8. Wang JC and Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. *Circ Res.* 2012; 111:245-259.
9. Brouillette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, Packard CJ and Samani NJ. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. *Lancet.* 2007; 369:107-114.
10. Fitzpatrick AL, Kronmal RA, Gardner JP, Psaty BM, Jenny NS, Tracy RP, Walston J, Kimura M and Aviv A. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. *Am J Epidemiol.* 2007; 165:14-21.
11. Panayiotou AG, Nicolaides AN, Griffin M, Tyllis T, Georgiou N, Bond D, Martin RM, Hoppensteadt D, Fareed J and Humphries SE. Leukocyte telomere length is associated with measures of subclinical atherosclerosis. *Atherosclerosis.* 2010; 211:176-181.
12. Samani NJ, Boulton R, Butler R, Thompson JR and Goodall AH. Telomere shortening in atherosclerosis. *Lancet.* 2001; 358:472-473.
13. De Meyer T, Rietzschel ER, De Buyzere ML, Langlois MR, De Bacquer D, Segers P, Van Damme P, De Backer GG, Van Oostveldt P, Van Criekinge W, Gillebert TC and Bekaert S. Systemic telomere length and preclinical atherosclerosis: the Asklepios Study. *Eur Heart J.* 2009; 30:3074-3081.
14. Farzaneh-Far R, Cawthon RM, Na B, Browner WS, Schiller NB and Whooley MA. Prognostic value of leukocyte telomere length in patients with stable coronary artery disease: data from the Heart and Soul Study. *Arterioscler Thromb Vasc Biol.* 2008; 28:1379-1384.
15. Astrup AS, Tarnow L, Jorsal A, Lajer M, Nzietchueng R, Benetos A, Rossing P and Parving HH. Telomere length predicts all-cause mortality in patients with type 1 diabetes. *Diabetologia.* 2010; 53:45-48.
16. Calvert PA, Liew TV, Gorenne I, Clarke M, Costopoulos C, Obaid DR, O'Sullivan M, Shapiro LM, McNab DC, Densem CG, Schofield PM, Braganza D, Clarke SC, et al. Leukocyte telomere length is associated with high-risk plaques on virtual histology intravascular ultrasound and increased proinflammatory activity. *Arterioscler Thromb Vasc Biol.* 2011; 31:2157-2164.
17. Huzen J, Peeters W, de Boer RA, Moll FL, Wong LS, Codd V, de Kleijn DP, de Smet BJ, van Veldhuisen DJ, Samani NJ, van Gilst WH, Pasterkamp G and van der Harst P. Circulating leukocyte and carotid atherosclerotic plaque telomere length: interrelation, association with plaque characteristics, and restenosis after endarterectomy. *Arterioscler Thromb Vasc Biol.* 2011; 31:1219-1225.
18. O'Donnell CJ, Demissie S, Kimura M, Levy D, Gardner JP, White C, D'Agostino RB, Wolf PA, Polak J, Cupples LA and Aviv A. Leukocyte telomere length and carotid artery intimal medial thickness: the Framingham Heart Study. *Arterioscler Thromb Vasc Biol.* 2008; 28:1165-1171.
19. Benetos A, Gardner JP, Zureik M, Labat C, Xiaobin L, Adamopoulos C, Temmar M, Bean KE, Thomas F and Aviv A. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. *Hypertension.* 2004; 43:182-185.
20. Mainous AG, 3rd, Codd V, Diaz VA, Schoepf UJ, Everett CJ, Player MS and Samani NJ. Leukocyte telomere length and coronary artery calcification. *Atherosclerosis.* 2010; 210:262-267.
21. Kark JD, Nassar H, Shaham D, Sinnreich R, Goldberger N, Aboudi V, Bogot NR, Kimura M and Aviv A. Leukocyte telomere length and coronary artery calcification in Palestinians. *Atherosclerosis.* 2013; 229:363-368.
22. Ando F, Takekuma K, Niino N and Shimokata H. Ultrasonic evaluation of common carotid intima-media thickness (IMT)--influence of local plaque on the relationship between IMT and age. *J Epidemiol.* 2000; 10:S10-17.
23. Johnsen SH, Mathiesen EB, Joakimsen O, Stensland E, Wilsgaard T, Lochen ML, Njolstad I and Arnesen E. Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: a 6-year follow-up study of 6226 persons: the Tromso Study. *Stroke.* 2007; 38(11):2873-2880.
24. Roman MJ, Kizer JR, Best LG, Lee ET, Howard BV, Shara NM and Devereux RB. Vascular biomarkers in the prediction of clinical cardiovascular disease: the Strong Heart Study. *Hypertension.* 2012; 59:29-35.
25. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB and Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. *N Engl J Med.* 2003; 349:2399-2406.
26. Roman MJ, Saba PS, Pini R, Spitzer M, Pickering TG, Rosen S, Alderman MH and Devereux RB. Parallel cardiac and vascular adaptation in hypertension. *Circulation.* 1992; 86:1909-1918.
27. Knoflach M, Kiechl S, Penz D, Zangerle A, Schmidauer C, Rossmann A, Shingh M, Spallek R, Griesmacher A, Bernhard D, Robatscher P, Buchberger W, Draxl W, et al. Cardiovascular risk factors and atherosclerosis in young women: atherosclerosis risk factors in female youngsters (ARFY study). *Stroke.* 2009; 40:1063-1069.
28. Polak JF, Tracy R, Harrington A, Zavodni AE and O'Leary DH. Carotid artery plaque and progression of coronary artery calcium: the multi-ethnic study of atherosclerosis. *J Am Soc Echocardiogr.* 2013; 26:548-555.
29. North KE, MacCluer JW, Devereux RB, Howard BV, Welty TK, Best LG, Lee ET, Fabsitz RR and Roman MJ. Heritability of carotid artery structure and function: the Strong Heart Family Study. *Arterioscler Thromb Vasc Biol.* 2002; 22:1698-1703.
30. Willeit P, Willeit J, Brandstatter A, Ehrlenbach S, Mayr A, Gasperi A, Weger S, Oberhollenzer F, Reindl M, Kronenberg F

and Kiechl S. Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. *Arterioscler Thromb Vasc Biol.* 2010; 30:1649-1656.

31. Aviv A, Hunt SC, Lin J, Cao X, Kimura M and Blackburn E. Impartial comparative analysis of measurement of leukocyte telomere length/DNA content by Southern blots and qPCR. *Nucleic Acids Res.* 2011; 39:e134.

32. Blackburn EH. The end of the (DNA) line. *Nat Struct Biol.* 2000; 7:847-850.

33. Gadalla SM, Cawthon R, Giri N, Alter BP and Savage SA. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. *Aging (Albany NY).* 2010; 2:867-874.

34. Lee ET, Welty TK, Fabsitz R, Cowan LD, Le NA, Oopik AJ, Cucchiara AJ, Savage PJ and Howard BV. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. *Am J Epidemiol.* 1990; 132:1141-1155.

35. North KE, Howard BV, Welty TK, Best LG, Lee ET, Yeh JL, Fabsitz RR, Roman MJ and MacCluer JW. Genetic and environmental contributions to cardiovascular disease risk in American Indians: the strong heart family study. *Am J Epidemiol.* 2003; 157:303-314.

36. Nambi V, Chambless L, Folsom AR, He M, Hu Y, Mosley T, Volcik K, Boerwinkle E and Ballantyne CM. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. *J Am Coll Cardiol.* 2010; 55:1600-1607.

37. Cawthon RM. Telomere measurement by quantitative PCR. *Nucleic Acids Res.* 2002; 30:e47.

38. Lin J, Epel E, Cheon J, Kroenke C, Sinclair E, Bigos M, Wolkowitz O, Mellon S and Blackburn E. Analyses and comparisons of telomerase activity and telomere length in human T and B cells: insights for epidemiology of telomere maintenance. *J Immunol Methods.* 2010; 352:71-80.

39. Zhao J, Zhu Y, Lin J, Matsuguchi T, Blackburn E, Zhang Y, Cole SA, Best LG, Lee ET and Howard BV. Short leukocyte telomere length predicts risk of diabetes in american indians: the strong heart family study. *Diabetes.* 2014; 63:354-362.

40. Zhu Y, Voruganti VS, Lin J, Matsuguchi T, Blackburn E, Best LG, Lee ET, MacCluer JW, Cole SA and Zhao J. QTL mapping of leukocyte telomere length in American Indians: the Strong Heart Family Study. *Aging (Albany NY).* 2013; 5:704-716.

41. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr. and Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension.* 2003; 42:1206-1252.

42. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care.* 1997; 20:1183-1197.

43. Kaplan EL and Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc.* 1958; 53:457-481.


44. Prentice RL and Kalbfleisch JD. Hazard rate models with covariates. *Biometrics.* 1979; 35:25-39.

45. Allison PD. *Survival Analysis Using SAS®: A Practical Guide*, Second Edition. Cary, NC: SAS Institute Inc. 2010.

46. Smith SC, Jr., Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients

with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. *J Am Coll Cardiol.* 2011; 58:2432-2446.

## SUPPLEMENTARY MATERIALS



**Figure S1.** Kaplan-Meier plots for survival function of incident carotid plaque in 2,091 American Indians free of prevalent CVD and carotid plaque at baseline.

**Table S1.** Prospective association of LTL with incidence and progression of carotid plaque using PROC LIFEREG

LTL	Regression coefficient	95% CI	P value
<b>Incident plaque (N=2,091)</b>			
<b>Model 1</b>			
Continuous LTL	0.17	0.04 - 0.30	0.01
Tertile 1 vs. Tertile 3	-0.10	-0.18 - -0.02	0.01
<b>Model 2</b>			
Continuous LTL	0.17	0.03 - 0.31	0.02
Tertile 1 vs. Tertile 3	-0.10	-0.17 - -0.02	0.02
<b>Model 3</b>			
Continuous LTL	0.15	0.006 - 0.29	0.04
Tertile 1 vs. Tertile 3	-0.09	-0.17 - -0.01	0.03
<b>Plaque progression (N=2,819)</b>			
<b>Model 1</b>			
Continuous LTL	0.20	0.09 - 0.32	0.0006
Tertile 1 vs. Tertile 3	-0.15	-0.21 - -0.08	<0.0001
<b>Model 2</b>			
Continuous LTL	0.18	0.07 - 0.30	0.002
Tertile 1 vs. Tertile 3	-0.14	-0.20 - -0.07	<0.0001
<b>Model 3</b>			
Continuous LTL	0.16	0.05 - 0.28	0.01
Tertile 1 vs. Tertile 3	-0.12	-0.19 - -0.06	0.0002

Model 1: adjusted for age at baseline, sex and study center

Model 2: additionally adjusted for BMI, current smoking and alcohol drinking status

Model 3: further adjusted for diabetes, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and estimated glomerular filtration rate

**Table S2.** Prospective association of LTL with incidence and progression of carotid plaque after excluding participants with prevalent diabetes at baseline

LTL	HR (95% CI)	P value
<b>Incident plaque (N=1,789)</b>		
<b>Model 1</b>		
Continuous LTL	0.34 ( 0.18- 0.66)	0.001
Tertile 1 vs. Tertile 3	1.65 ( 1.17- 2.33)	0.005
<b>Model 2</b>		
Continuous LTL	0.35 ( 0.18- 0.67)	0.002
Tertile 1 vs. Tertile 3	1.66 ( 1.17- 2.36)	0.004
<b>Model 3</b>		
Continuous LTL	0.37 ( 0.19- 0.73)	0.004
Tertile 1 vs. Tertile 3	1.62 ( 1.14- 2.31)	0.007
<b>Plaque progression (N=2,233)</b>		
<b>Model 1</b>		
Continuous LTL	0.34 (0.20 - 0.58)	<0.0001
Tertile 1 vs. Tertile 3	1.81 (1.36 - 2.41)	<0.0001
<b>Model 2</b>		
Continuous LTL	0.36 (0.21 - 0.62)	0.0002
Tertile 1 vs. Tertile 3	1.77 (1.33 - 2.35)	<0.0001
<b>Model 3</b>		
Continuous LTL	0.41 (0.24 - 0.70)	0.001
Tertile 1 vs. Tertile 3	1.69 (1.27 - 2.25)	0.0003

Model 1: adjusted for age at baseline, sex and study center

Model 2: additionally adjusted for BMI, current smoking and alcohol drinking status

Model 3: further adjusted for diabetes, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and estimated glomerular filtration rate

**Table S3.** Prospective association of LTL with incidence and progression of carotid plaque after excluding participants with prevalent diabetes or hypertension at baseline

LTL	HR (95% CI)	P value
<b>Incident plaque (N=1,504)</b>		
<b>Model 1</b>		
Continuous LTL	0.31 ( 0.15- 0.64)	0.002
Tertile 1 vs. Tertile 3	1.72 ( 1.16- 2.56)	0.007
<b>Model 2</b>		
Continuous LTL	0.32 ( 0.15- 0.69)	0.004
Tertile 1 vs. Tertile 3	1.76 ( 1.18- 2.63)	0.006
<b>Model 3</b>		
Continuous LTL	0.39 ( 0.18- 0.82)	0.01
Tertile 1 vs. Tertile 3	1.74 ( 1.17- 2.60)	0.007
<b>Plaque progression (N=1,749)</b>		
<b>Model 1</b>		
Continuous LTL	0.37 ( 0.20 - 0.68)	0.001
Tertile 1 vs. Tertile 3	1.85 ( 1.32 - 2.60)	0.0003
<b>Model 2</b>		
Continuous LTL	0.41 ( 0.22 - 0.76)	0.004
Tertile 1 vs. Tertile 3	1.80 ( 1.28 - 2.53)	0.0007
<b>Model 3</b>		
Continuous LTL	0.45 ( 0.24 - 0.82)	0.01
Tertile 1 vs. Tertile 3	1.77 ( 1.26 - 2.49)	0.001

Model 1: adjusted for age at baseline, sex and study center

Model 2: additionally adjusted for BMI, current smoking and alcohol drinking status

Model 3: further adjusted for diabetes, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and estimated glomerular filtration rate